RxDoctor Payments Data

William Simon, MD

Internal Medicine · Oceanside, NYNPI 1134102049

Payments from drug & device makers

$60,666in general payments, 2019–2025

Across 224 payments — averaging $270.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Esperion Therapeutics, Inc.$58K
  • Boehringer Ingelheim$931
  • Lilly USA, LLC$410
  • Novo Nordisk$232
  • AstraZeneca$216
  • Amarin Pharma, Inc.$165
  • plus $841 from 9 others

What the payments were for

  • Food & beverage$2,862100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$60,666 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$419,779
Medicare patients
446
Services billed
10,742

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin54$80,000
MounjaroTirzepatide55$61,597
TradjentaLinagliptin41$57,080
OzempicSemaglutide41$45,125
XareltoRivaroxaban28$32,315
JanuviaSitagliptin Phosphate20$32,104
FarxigaDapagliflozin Propanediol19$27,128
TrulicityDulaglutide20$19,448
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$11,761
EliquisApixaban18$11,261
Valsartan281$7,579
Repatha SureclickEvolocumab11$5,949
Atorvastatin Calcium464$3,930
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide113$3,559
Levothyroxine Sodium203$3,169

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$931$137,08095 claims
Lilly USA, LLCMounjaro, Trulicity$410$81,04575 claims
Novo NordiskOzempic$232$45,12541 claims
AstraZenecaFarxiga, Breztri Aerosphere$216$38,88934 claims
Johnson & JohnsonXarelto$45$32,31528 claims
MerckJanuvia$115$32,10420 claims
PfizerEliquis$102$11,26118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Oceanside

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →